Actionable news
0
All posts from Actionable news
Actionable news in PRAN: Prana Biotechnology Ltd,

The novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease”

Exhibit 99.1

Prana’s PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

Scientific Journal Acta Neuropathologica publishes pre-clinical data

MELBOURNE, Australia, and San Francisco USA 3 July 2017: Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) today announced the article “was accepted for publication in the peer reviewed journal Acta Neuropathologica Communications. The peer reviewed article can be accessed from the following website:

https://actaneurocomms.biomedcentral.com/articles/10.1186/s4...

The publication is the culmination of ten years of research from scientists at the Florey Institute of Neuroscience and Mental Health, (Melbourne, Australia), investigating compounds from Prana Biotechnology’s propriety chemical library. The novel drug candidate PBT434 is the first of a new generation of small molecules from the quinazolinone class of drugs that was specifically designed to block the accumulation and aggregation of alpha-synuclein, an abundant brain protein widely believed to be involved in the pathogenesis of Parkinson’s disease and related disorders.

Not only was PBT434 shown to block alpha-synuclein accumulation, but it also prevented loss of nerve cells in the region of the brain primarily affected in Parkinson’s disease, called the substantia nigra. To investigate the therapeutic potential of PBT434 to slow neurodegeneration, the researchers performed extensive animal testing in multiple Parkinson’s disease models, including tests in mice that over-expressed the alpha-synuclein protein. These results showed that PBT434 lowered alpha-synuclein and its toxic effects and simultaneously improved motor performance.

If these findings are also observed in patients with diseases caused by alpha-synuclein, PBT434 could...


More